share_log

Humanigen's Ifabotuzumab Shows Encouraging Action In Early-Stage Brain Cancer Study

Humanigen's Ifabotuzumab Shows Encouraging Action In Early-Stage Brain Cancer Study

Humanigen公司的Ifaotuzumab在早期脑癌研究中显示出令人鼓舞的作用
Benzinga Real-time News ·  2021/04/09 20:28
  • Humanigen Inc (NASDAQ: HGEN) has announced results from the Phase 1 trial evaluating its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM), the most frequent and lethal primary brain cancer.
  • The results will be presented as a poster at the AACR Annual Meeting 2021.
  • In the study, ifabotuzumab demonstrated highly sensitive, specific, and reproducible targeting of the tumor and tumor microenvironment in all patients.
  • No dose-limiting toxicities were observed, and all adverse events were readily manageable.
  • The Phase 1 study was designed to determine the safety and recommended Phase 2 dose of ifabotuzumab.
  • Ifabotuzumab is a non-fucosylated IgG1κ antibody targeting the EphA3 receptor. EphA3 is a tumor-restricted antigen expressed in the tumor vasculature and tumor stroma of various solid tumors.
  • Additional studies are planned to evaluate ifabotuzumab as an antibody-drug conjugate in solid tumor patients.
  • Price Action: HGEN shares are trading 2.8% higher at $17.4 in the premarket session on the last check Friday.
  • Humanigen Inc.纳斯达克市场代码：HGEN)宣布了评估其第二种Humaneered抗体ifobtuzumab的第一阶段试验结果，该抗体用于治疗多形性胶质母细胞瘤(GBM)患者，GBM是最常见和最致命的原发性脑癌。
  • 结果将以海报的形式在AACR 2021年年会上公布。
  • 在这项研究中，ifobtuzumab对所有患者的肿瘤和肿瘤微环境显示出高度敏感、特异和可重复性的靶向。
  • 没有观察到剂量限制毒性，所有不良事件都很容易控制。
  • 第一阶段研究的目的是确定ifobtuzumab的安全性和推荐的第二阶段剂量。
  • Ifaotuzumab是一种针对EphA3受体的非岩藻糖基化IgG1型κ抗体。EphA3是一种肿瘤限制性抗原，表达于多种实体瘤的肿瘤血管和肿瘤间质中。
  • 计划进行更多的研究来评估ifobtuzumab作为实体肿瘤患者的抗体-药物结合物。
  • 价格行动：在周五的最后一次检查中，HGEN股价在盘前交易时段上涨2.8%，至17.4美元。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发